Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1892 1
1896 3
1897 1
1898 3
1899 4
1900 2
1901 2
1902 1
1903 1
1905 9
1906 4
1907 4
1908 7
1909 16
1910 12
1911 15
1912 12
1913 15
1914 9
1915 23
1916 25
1917 25
1918 27
1919 27
1920 22
1921 28
1922 31
1923 41
1924 28
1925 50
1926 35
1927 42
1928 53
1929 48
1930 42
1931 42
1932 40
1933 27
1934 31
1935 50
1936 54
1937 38
1938 56
1939 42
1940 46
1941 40
1942 41
1943 35
1944 30
1945 148
1946 406
1947 432
1948 429
1949 357
1950 630
1951 647
1952 665
1953 979
1954 1047
1955 1214
1956 1152
1957 1162
1958 1220
1959 1324
1960 1548
1961 1935
1962 2316
1963 3874
1964 5554
1965 4845
1966 5280
1967 6634
1968 8155
1969 9704
1970 10534
1971 11444
1972 11953
1973 13042
1974 13623
1975 13925
1976 13621
1977 13827
1978 14147
1979 14973
1980 15402
1981 16471
1982 17850
1983 20044
1984 21836
1985 23812
1986 25359
1987 29024
1988 32976
1989 35578
1990 37485
1991 38242
1992 38506
1993 39008
1994 39833
1995 39986
1996 39525
1997 39016
1998 39772
1999 39995
2000 42020
2001 42212
2002 42417
2003 44157
2004 46449
2005 49597
2006 51800
2007 53902
2008 55814
2009 57779
2010 61364
2011 65398
2012 68613
2013 72348
2014 82627
2015 88828
2016 93078
2017 94833
2018 99115
2019 104168
2020 113807
2021 120516
2022 112741
2023 102499
2024 34960

Text availability

Article attribute

Article type

Publication date

Search Results

2,421,074 results

Results by year

Filters applied: . Clear all
Page 1
Considerations for the Design of Antibody-Based Therapeutics.
Goulet DR, Atkins WM. Goulet DR, et al. J Pharm Sci. 2020 Jan;109(1):74-103. doi: 10.1016/j.xphs.2019.05.031. Epub 2019 Jun 4. J Pharm Sci. 2020. PMID: 31173761 Free PMC article. Review.
Antibody-based proteins have become an important class of biologic therapeutics, due in large part to the stability, specificity, and adaptability of the antibody framework. ...Thus, several derivatives of the monoclonal antibody format, including bispecific …
Antibody-based proteins have become an important class of biologic therapeutics, due in large part to the stability, specificity, and …
Antibody Purification and Storage.
Fishman JB, Berg EA. Fishman JB, et al. Cold Spring Harb Protoc. 2019 May 1;2019(5). doi: 10.1101/pdb.top099101. Cold Spring Harb Protoc. 2019. PMID: 31043563 Review.
Antibodies have become a common and necessary tool in biochemistry, cell biology, and immunology laboratories. There are many different types of antibodies and antibody fragments being used for a myriad of applications. ...
Antibodies have become a common and necessary tool in biochemistry, cell biology, and immunology laboratories. There are many …
Engineering antibody therapeutics.
Chiu ML, Gilliland GL. Chiu ML, et al. Curr Opin Struct Biol. 2016 Jun;38:163-73. doi: 10.1016/j.sbi.2016.07.012. Epub 2016 Aug 12. Curr Opin Struct Biol. 2016. PMID: 27525816 Free article. Review.
The successful introduction of antibody-based protein therapeutics into the arsenal of treatments for patients has within a few decades fostered intense innovation in the production and engineering of antibodies. Reviewed here are the methods currently used to produ …
The successful introduction of antibody-based protein therapeutics into the arsenal of treatments for patients has within a few decad …
Monoclonal versus polyclonal antibodies: distinguishing characteristics, applications, and information resources.
Lipman NS, Jackson LR, Trudel LJ, Weis-Garcia F. Lipman NS, et al. ILAR J. 2005;46(3):258-68. doi: 10.1093/ilar.46.3.258. ILAR J. 2005. PMID: 15953833 Review.
Antibodies are host proteins that comprise one of the principal effectors of the adaptive immune system. ...They are also becoming an important therapeutic tool in the clinician's armamentarium to treat disease. Antibodies are utilized for analysis, purification, an …
Antibodies are host proteins that comprise one of the principal effectors of the adaptive immune system. ...They are also becoming an …
The Immunoglobulins: New Insights, Implications, and Applications.
Sun Y, Huang T, Hammarström L, Zhao Y. Sun Y, et al. Annu Rev Anim Biosci. 2020 Feb 15;8:145-169. doi: 10.1146/annurev-animal-021419-083720. Epub 2019 Dec 17. Annu Rev Anim Biosci. 2020. PMID: 31846352 Review.
Immunoglobulins (Igs), as one of the hallmarks of adaptive immunity, first arose approximately 500 million years ago with the emergence of jawed vertebrates. Two events stand out in the evolutionary history of Igs from cartilaginous fish to mammals: (a) the diversification …
Immunoglobulins (Igs), as one of the hallmarks of adaptive immunity, first arose approximately 500 million years ago with the emergen …
Antibody pharmacokinetics and pharmacodynamics.
Lobo ED, Hansen RJ, Balthasar JP. Lobo ED, et al. J Pharm Sci. 2004 Nov;93(11):2645-68. doi: 10.1002/jps.20178. J Pharm Sci. 2004. PMID: 15389672 Review.
Food and Drug administration (FDA) has approved several polyclonal antibody preparations and at least 18 monoclonal antibody preparations (antibodies, antibody fragments, antibody fusion proteins, etc.). ...Antibody administration may ind …
Food and Drug administration (FDA) has approved several polyclonal antibody preparations and at least 18 monoclonal antibody p …
Sialylation as an Important Regulator of Antibody Function.
Vattepu R, Sneed SL, Anthony RM. Vattepu R, et al. Front Immunol. 2022 Apr 7;13:818736. doi: 10.3389/fimmu.2022.818736. eCollection 2022. Front Immunol. 2022. PMID: 35464485 Free PMC article. Review.
In serum, IgG is the most abundant antibody, comprising 75% of antibodies in circulation, followed by IgA at 15%, IgM at 10%, and IgD and IgE are the least abundant. All human antibody classes are post-translationally modified by sugars. The resulting glycans …
In serum, IgG is the most abundant antibody, comprising 75% of antibodies in circulation, followed by IgA at 15%, IgM at 10%, …
Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells.
Cao Y, Su B, Guo X, Sun W, Deng Y, Bao L, Zhu Q, Zhang X, Zheng Y, Geng C, Chai X, He R, Li X, Lv Q, Zhu H, Deng W, Xu Y, Wang Y, Qiao L, Tan Y, Song L, Wang G, Du X, Gao N, Liu J, Xiao J, Su XD, Du Z, Feng Y, Qin C, Qin C, Jin R, Xie XS. Cao Y, et al. Cell. 2020 Jul 9;182(1):73-84.e16. doi: 10.1016/j.cell.2020.05.025. Epub 2020 May 18. Cell. 2020. PMID: 32425270 Free PMC article.
Additionally, the 3.8 A cryo-EM structure of a neutralizing antibody in complex with the spike-ectodomain trimer revealed the antibody's epitope overlaps with the ACE2 binding site. Moreover, we demonstrated that SARS-CoV-2-neutralizing antibodies coul …
Additionally, the 3.8 A cryo-EM structure of a neutralizing antibody in complex with the spike-ectodomain trimer revealed the anti …
Monoclonal antibody pharmacokinetics and pharmacodynamics.
Wang W, Wang EQ, Balthasar JP. Wang W, et al. Clin Pharmacol Ther. 2008 Nov;84(5):548-58. doi: 10.1038/clpt.2008.170. Epub 2008 Sep 10. Clin Pharmacol Ther. 2008. PMID: 18784655
More than 20 monoclonal antibodies have been approved as therapeutic drugs by the US Food and Drug Administration, and it is quite likely that the number of approved antibodies will double in the next 7-10 years. ...In addition, antibody administration often …
More than 20 monoclonal antibodies have been approved as therapeutic drugs by the US Food and Drug Administration, and it is quite li …
Antibody effector functions are associated with protection from respiratory syncytial virus.
Bartsch YC, Cizmeci D, Kang J, Zohar T, Periasamy S, Mehta N, Tolboom J, Van der Fits L, Sadoff J, Comeaux C, Callendret B, Bukreyev A, Lauffenburger DA, Bastian AR, Alter G. Bartsch YC, et al. Cell. 2022 Dec 22;185(26):4873-4886.e10. doi: 10.1016/j.cell.2022.11.012. Epub 2022 Dec 12. Cell. 2022. PMID: 36513064 Free article.
With no effective prophylactic treatment available, current vaccine candidates aim to elicit neutralizing antibodies. However, binding and neutralization have poorly predicted protection in the past, and accumulating data across epidemiologic cohorts and animal models coll …
With no effective prophylactic treatment available, current vaccine candidates aim to elicit neutralizing antibodies. However, bindin …
2,421,074 results
You have reached the last available page of results. Please see the User Guide for more information.